Starling is a YC and AARP backed startup building an at-home urinalysis medical device, UrinDx, that uses advanced spectroscopy and machine learning to manage chronic health conditions. Our first product is our urinary tract infection (UTI) prevention platform, and we plan to expand our FDA clearances to Chronic Kidney Disease and Bladder Cancer in subsequent submissions.
Last year, Starling's UTI prevention program received successful reimbursement from Aetna, BCBS, and Medicare during their 40 patient pilot over 12 months. Today, after securing a contract with the largest chronic care coordination partner in Urology, we are raising a seed extension of $1.5M at $11M pre, of which $500k is still available for outsiders, to support scaling our commercial launch to 2,000 patients, $1.5M ARR, with 4 Large Urology Group Partner Association sites in 2026, contracts worth over $20M ARR at scale.
In addition to YC and AARP, our investors include Wellstar Health System, Innospark Ventures, Rebel Fund, Magic Fund and a confidential strategic, who is funding our current clinical trial and is a potential future acquirer.
